10.7 C
Munich
Sunday, May 26, 2024

Quanterix launches LucentAD biomarker test for early Alzheimer’s disease (NASDAQ:QTRX)

Must read

- Advertisement -


Alzheimers Disease concept , Brain degenerative diseases Parkinson

juststock

Quanterix (NASDAQ:QTRX) said that it has launched a biomarker blood test called LucentAD to help diagnose patients experiencing symptoms consistent with early Alzheimer’s disease, or AD.

The diagnostics company said the test allows healthcare professionals to quickly assess the patient

- Advertisement -



Source link

- Advertisement -

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article